• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Predictive Oncology Inc.

    4/18/25 2:37:31 PM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email
    424B5 1 f424b5_041825.htm FORM 424B5

    As Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-279123

    PROSPECTUS SUPPLEMENT

    (To Prospectus and Prospectus Supplement dated May 21, 2024)

     

    Up to $1,491,000

    Common Stock

     

    This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3 (333-279123), as supplemented by our prospectus supplement, dated May 21, 2024 (together, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the ATM Sales Agreement, dated May 3, 2024 (the “Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. During the twelve calendar months prior to, and including, the date hereof, we have sold an aggregate of 1,607,100 shares of our common stock for aggregate gross proceeds of approximately $3,696,000 through Wainwright under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto.

     

    As of the date of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $17,195,985, which was calculated based on 8,818,454 shares of our outstanding common stock held by non-affiliates and a price of $1.95 per share, the closing price of our common stock on February 18, 2025, which is the highest closing sale price of our common stock on the Nasdaq Capital Market within the prior 60 days. As of the date of this Prospectus Supplement, we have sold securities with an aggregate market value of approximately $4,240,852 pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12 calendar month period so long as our public float remains below $75.0 million.

     

    We are filing this Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell, and to specify the value of common stock we would be permitted to sell in any 12 calendar month period under General Instruction I.B.6. We may currently only offer and sell shares of our common stock having an aggregate offering price of up to $1,491,000 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement, and as a result of the limitations set forth in General Instruction I.B.6, the maximum amount of shares we are eligible to sell in any 12 calendar month period as a result of these limitations is approximately $1,491,000. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales. 

     

    Our common stock trades on the Nasdaq Capital Market under the symbol “POAI.” On April 17, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $0.9355 per share.

     

     

     

    INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-9 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

     

    H.C. Wainright & Co.

     

    The date of this prospectus supplement is April 18, 2025.

     

     

     

    Get the next $POAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

      New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens Builds upon Predictive's biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today that it has made significant progress along the continuum of biomarker discovery, drug discovery and drug repurposing. These latest developments build upon Predictive's ongoing initiative to combine its in-house biomarker identification platform with its AI screening capabilit

      4/15/25 8:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Renovaro Provides Update to Definitive Agreement with Predictive Oncology

      LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025

      4/4/25 9:40:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

      PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024. On January 6, 2025, Predictive Oncology announced that it has entered into an agreement to merg

      4/1/25 7:00:18 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    SEC Filings

    See more
    • SEC Form 424B5 filed by Predictive Oncology Inc.

      424B5 - Predictive Oncology Inc. (0001446159) (Filer)

      4/18/25 2:37:31 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Amendment: Predictive Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K/A - Predictive Oncology Inc. (0001446159) (Filer)

      4/18/25 2:21:17 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Predictive Oncology Inc. (0001446159) (Filer)

      4/7/25 9:05:49 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

      SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

      2/11/22 7:50:59 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

      3/1/21 6:23:16 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

      H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      8/19/24 6:55:24 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

      HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

      6/30/21 6:22:58 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

      Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      2/1/21 10:17:27 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Financials

    Live finance-specific insights

    See more
    • Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

      PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

      11/13/24 7:00:21 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

      PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

      8/14/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

      PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas

      8/7/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Leadership Updates

    Live Leadership Updates

    See more
    • AIRNA Appoints Matthew Hawryluk as Chief Business Officer

      AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

      1/30/25 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Renovaro Issues Shareholder Letter and Provides Corporate Update

      Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

      1/7/25 9:15:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

      EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas

      6/27/23 8:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • St. Clair Gregory Sr was granted 3,268 shares, increasing direct ownership by 17% to 22,534 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:48 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Hawryluk Matthew was granted 2,368 shares, increasing direct ownership by 33% to 9,488 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:26 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Rao Veena was granted 3,268 shares, increasing direct ownership by 56% to 9,117 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:19 PM ET
      $POAI
      Industrial Specialties
      Health Care